LY2963016 + Lantus + Insulin Lispro

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 1

Conditions

Diabetes Mellitus, Type 1

Trial Timeline

Aug 1, 2011 โ†’ Apr 1, 2013

About LY2963016 + Lantus + Insulin Lispro

LY2963016 + Lantus + Insulin Lispro is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT01421147. Target conditions include Diabetes Mellitus, Type 1.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01421147Phase 3Completed